Liesel FitzGerald

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5689473/publications.pdf Version: 2024-02-01



LIESEL FITZCEDALD

#	Article	IF	CITATIONS
1	Analysis of a large prostate cancer family identifies novel and recurrent gene fusion events providing evidence for inherited predisposition. Prostate, 2022, 82, 540-550.	2.3	3
2	Urban–rural prostate cancer disparities in a regional state of Australia. Scientific Reports, 2022, 12, 3022.	3.3	4
3	The effect of insulin on response to intravitreal anti-VEGF injection in diabetic macular edema in type 2 diabetes mellitus. BMC Ophthalmology, 2022, 22, 94.	1.4	2
4	ldentifying Genetic Biomarkers Predicting Response to Anti-Vascular Endothelial Growth Factor Injections in Diabetic Macular Edema. International Journal of Molecular Sciences, 2022, 23, 4042.	4.1	5
5	Two-stage Study of Familial Prostate Cancer by Whole-exome Sequencing and Custom Capture Identifies 10 Novel Genes Associated with the Risk of Prostate Cancer. European Urology, 2021, 79, 353-361.	1.9	28
6	A rare variant in <scp><i>EZH2</i></scp> is associated with prostate cancer risk. International Journal of Cancer, 2021, 149, 1089-1099.	5.1	9
7	Comparing vision and macular thickness in neovascular age-related macular degeneration, diabetic macular oedema and retinal vein occlusion patients treated with intravitreal antivascular endothelial growth factor injections in clinical practice. BMJ Open Ophthalmology, 2021, 6, e000749.	1.6	3
8	Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study. European Urology Oncology, 2021, 4, 570-579.	5.4	38
9	Evaluation of Hypofractionated Radiation Therapy Use and Patient-Reported Outcomes in Men With Nonmetastatic Prostate Cancer in Australia and New Zealand. JAMA Network Open, 2021, 4, e2129647.	5.9	13
10	Massively parallel sequencing in hereditary prostate cancer families reveals a rare risk variant in the DNA repair gene, RAD51C. European Journal of Cancer, 2021, 159, 52-55.	2.8	3
11	Cumulative Burden of Colorectal Cancer–Associated Genetic Variants Is More Strongly Associated With Early-Onset vs Late-Onset Cancer. Gastroenterology, 2020, 158, 1274-1286.e12.	1.3	110
12	Identifying Genetic Risk Factors for Diabetic Macular Edema and the Response to Treatment. Journal of Diabetes Research, 2020, 2020, 1-12.	2.3	8
13	Novel Common Genetic Susceptibility Loci for Colorectal Cancer. Journal of the National Cancer Institute, 2019, 111, 146-157.	6.3	129
14	Pharmacogenomic Biomarkers in Docetaxel Treatment of Prostate Cancer: From Discovery to Implementation. Genes, 2019, 10, 599.	2.4	17
15	A fourâ€gene transcript score to predict metastaticâ€ŀethal progression in men treated for localized prostate cancer: Development and validation studies. Prostate, 2019, 79, 1589-1596.	2.3	8
16	Discovery of common and rare genetic risk variants for colorectal cancer. Nature Genetics, 2019, 51, 76-87.	21.4	377
17	Germline variants in IL4, MGMT and AKT1 are associated with prostate cancer-specific mortality: An analysis of 12,082 prostate cancer cases. Prostate Cancer and Prostatic Diseases, 2018, 21, 228-237.	3.9	8
18	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nature Genetics, 2018, 50, 928-936.	21.4	652

LIESEL FITZGERALD

#	Article	IF	CITATIONS
19	Impact of the G84E variant on HOXB13 gene and protein expression in formalin-fixed, paraffin-embedded prostate tumours. Scientific Reports, 2017, 7, 17778.	3.3	8
20	Whole exome sequencing in 75 high-risk families with validation and replication in independent case-control studies identifies <i>TANGO2</i> , <i>OR5H14</i> , and <i>CHAD</i> as new prostate cancer susceptibility genes. Oncotarget, 2017, 8, 1495-1507.	1.8	11
21	Use of a Novel Nonparametric Version of DEPTH to Identify Genomic Regions Associated with Prostate Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1619-1624.	2.5	7
22	Investigation of the Relationship Between Prostate Cancer and <i>MSMB</i> and <i>NCOA4</i> Genetic Variants and Protein Expression. Human Mutation, 2013, 34, 149-156.	2.5	26
23	Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nature Genetics, 2013, 45, 385-391.	21.4	492
24	Germline Missense Variants in the <i>BTNL2</i> Gene Are Associated with Prostate Cancer Susceptibility. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1520-1528.	2.5	35
25	Genome-wide Association Study Identifies a Genetic Variant Associated with Risk for More Aggressive Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1196-1203.	2.5	48
26	Genetic Variants in the <i>LEPR</i> , <i>CRY1</i> , <i>RNASEL</i> , <i>IL4</i> , and <i>ARVCF</i> Genes Are Prognostic Markers of Prostate Cancer-Specific Mortality. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1928-1936.	2.5	68
27	Genome-wide linkage analyses of hereditary prostate cancer families with colon cancer provide further evidence for a susceptibility locus on 15q11–q14. European Journal of Human Genetics, 2010, 18, 1141-1147.	2.8	7
28	Association of FGFR4 genetic polymorphisms with prostate cancer risk and prognosis. Prostate Cancer and Prostatic Diseases, 2009, 12, 192-197.	3.9	28
29	Dense genome-wide SNP linkage scan in 301 hereditary prostate cancer families identifies multiple regions with suggestive evidence for linkage. Human Molecular Genetics, 2009, 18, 1839-1848.	2.9	25
30	Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer, 2008, 8, 230.	2.6	145
31	Effect of MELANOTAN®, [Nle4, D-Phe7]-α-MSH, on melanin synthesis in humans with MC1R variant alleles. Peptides, 2006, 27, 388-394.	2.4	35